Browsing Tag
The New England Journal of Medicine
4 posts
Bristol Myers Squibb (NYSE: BMY) strengthens Camzyos growth case with positive adolescent SCOUT-HCM data
Bristol Myers Squibb’s Camzyos cleared a key adolescent Phase 3 hurdle in oHCM. Read what the SCOUT-HCM data could mean for growth and competition.
United Therapeutics (NASDAQ: UTHR) pushes inhaled therapy strategy as Phase 3 Tyvaso data shows lung function preservation in IPF
United Therapeutics reports strong Phase 3 TETON-2 results for Tyvaso in idiopathic pulmonary fibrosis. Discover why this inhaled therapy could reshape treatment.
Winrevair slashes early PAH worsening by 76% in phase 3 Hyperion, but can it reset first-year care?
Winrevair reduced PAH clinical worsening by 76% in phase 3 Hyperion. Learn how Merck’s results could reset first-year treatment guidelines today.
Zepbound outperforms Wegovy in SURMOUNT-5 trial: Eli Lilly’s weight-loss drug achieves 47% greater relative reduction
Zepbound outperforms Wegovy with 20.2% weight loss in SURMOUNT-5 trial. See how Eli Lilly’s stock and investor sentiment responded to this clinical milestone.